News

  • BrainsWay Ltd. Q3 2018 results – conference call November 13,  2018
    13 November, 2018 - ,

    BrainsWay Ltd. Q3 2018 results – conference call November 13, 2018

      (more…)

    Read More
  • BrainsWay to Showcase FDA-Cleared Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at DGPPN 2018
    13 November, 2018 - ,

    BrainsWay to Showcase FDA-Cleared Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at DGPPN 2018

    Meet BrainsWay at the German Association for Psychiatry, Psychotherapy and Psychosomatics Annual Congress (DGPPN 2018) in Berlin 28 November – 1 December 2018

    Read More
  • BrainsWay to Showcase Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at the 2018 Annual Psych Congress
    17 October, 2018 - ,

    BrainsWay to Showcase Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at the 2018 Annual Psych Congress

    Showcase represents the public debut of BrainsWay’s Deep TMS system for OCD  Healthcare providers will be able to view demonstrations of and purchase the BrainsWay system

    Read More
  • BrainsWay Announces First Shipments of Deep Transcranial Magnetic Stimulation Helmets for the Treatment of Obsessive-Compulsive Disorder
    10 October, 2018 - ,

    BrainsWay Announces First Shipments of Deep Transcranial Magnetic Stimulation Helmets for the Treatment of Obsessive-Compulsive Disorder

    Twenty sites across the U.S. are the first to receive the BrainsWay Deep transcranial magnetic stimulation system (Deep TMS) for obsessive-compulsive disorder (OCD) 

    Read More
  • BrainsWay Reports Financial Results for Second Quarter of 2018 and Provides Corporate Update
    27 August, 2018 - ,

    BrainsWay Reports Financial Results for Second Quarter of 2018 and Provides Corporate Update

    Second quarter revenues of $3.7 million represent a quarterly record and a 57% increase over second quarter 2017 Recently announced FDA clearance of Deep TMS system for treatment

    Read More
  • BrainsWay Receives First Ever FDA Clearance of a Non-Invasive Device for Treatment of Obsessive-Compulsive Disorder
    19 August, 2018 - ,

    BrainsWay Receives First Ever FDA Clearance of a Non-Invasive Device for Treatment of Obsessive-Compulsive Disorder

    BrainsWay’s deep transcranial magnetic stimulation (Deep TMS) system is a best-in-class device designed to maximize electromagnetic stimulation of deep and broad brain regions, helping to launch a

    Read More
  • BrainsWay Reports Record Financial Results for First Quarter of 2018 and Provides Corporate Update
    30 May, 2018 - ,

    BrainsWay Reports Record Financial Results for First Quarter of 2018 and Provides Corporate Update

    First quarter revenues of $3.6 million represent a quarterly record and a  68% increase over first quarter 2017 Increased market demand and leasing model continue to generate sales

    Read More
  • Achieve TMS Announces Grand Opening of New Location in Newton, Massachusetts
    6 May, 2018 - ,

    Achieve TMS Announces Grand Opening of New Location in Newton, Massachusetts

    NEWTON, Mass., May 23, 2018 (GLOBE NEWSWIRE) — Achieve TMS, the largest U.S. provider of BrainsWay’s

    Read More
  • BrainsWay Receives FDA Clearance of Next Generation Stimulator, Enhancing Its Current Deep Transcranial Magnetic Stimulation (Deep TMS) System for Treatment of Major Depressive Disorder
    6 May, 2018 - ,

    BrainsWay Receives FDA Clearance of Next Generation Stimulator, Enhancing Its Current Deep Transcranial Magnetic Stimulation (Deep TMS) System for Treatment of Major Depressive Disorder

    The company will now have the most advanced stimulator on the market, with enhanced features that increase the ease of use for physicians and integrate a patient management

    Read More
  • Brainsway Raises $8.5 Million From Leading Israeli Investors
    12 December, 2017 - ,

    Brainsway Raises $8.5 Million From Leading Israeli Investors

    Phoenix Group becomes 7% shareholder. financing strengthens Brainsway’s balance sheet and provides strong support for continued growth HACKENSACK, N.J., Dec. 12, 2017 – Brainsway

    Read More